Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Awards
Stanley Institute awards $3.8 million for developing cognitive deficit therapy
June 6th, 2005
Saegis Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing medicines that protect and enhance the function of the human mind, announced that The Stanley Medical Research Institute (SMRI) is providing Saegis with up to $3.8 million to continue funding human clinical trials of SGS518. Saegis is developing SGS518 as a treatment for the cognitive deficit that occurs in schizophrenia. This is the second award that Saegis has received from SMRI for this therapeutic clinical development program. In January, 2004, Saegis received a $2 million investment from The Stanley Medical Research Institute to support the initiation...
Source: Biotech Business Week (2005-06-06)
|
